CVS Health Q1 2026 Earnings Beat Expectations, Revenue Up 6.2%
CVS Health reported strong Q1 2026 results with revenue of $100.4B and adjusted EPS of $2.57, reinforcing its position as a cheap stock for the next decade.
Key Numbers
CVS Health Corporation (NYSE:CVS) reported its first-quarter 2026 results on May 6, with total revenues increasing 6.2% year-over-year to $100.4 billion. The company posted GAAP diluted EPS of $2.30 and adjusted EPS of $2.57, up from $1.41 in the prior-year period. This strong performance comes as the stock is considered one of the cheap stocks to buy for the next 10 years.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 (est.) | Change |
|---|---|---|---|
| Revenue | $100.4B | $94.5B | +6.2% |
| GAAP EPS | $2.30 | $1.41 | +63% |
| Adjusted EPS | $2.57 | $1.41 | +82% |
Highlights from the Release
The company attributed revenue growth to strong performance in healthcare and pharmacy segments, as well as increased enrollment in health insurance plans. Cost-cutting measures also contributed to margin improvement.
Guidance
CVS did not provide specific quarterly guidance but reiterated its commitment to achieving its 2026 annual targets.
Stock Impact
Despite the positive results, the stock price saw no significant change immediately after the announcement, possibly reflecting already optimistic market expectations. However, analysts believe the stock remains undervalued.
What This Means for Investors
CVS Health's results demonstrate its ability to deliver strong revenue and earnings growth, reinforcing its appeal as a long-term investment. However, investors should assess risks related to the healthcare sector and competition.
Frequently Asked Questions
Found this useful? Share it